Review Papers Claim by Claim

Visual, evidence-weighted review — Diep et al., 2019 (SETD3 & enteroviruses)

Figure: simplified reproduction of the paper's central quantitative finding: SETD3KO causes ~10^3-fold reduction in enteroviral RNA for multiple representative human enteroviruses (values plotted as % of WT; SETD3KO ~0.1% = ~1,000-fold reduction). Data summarized from Diep et al. 2019 and main text/figures Diep et al., main quantitative results

Figure: experimental rescue — catalytically inactive SETD3-5M restores replication similarly to WT SETD3, demonstrating that methyltransferase catalytic activity (actin-H73 methylation) is not required for proviral function. Quantitative mass-spectrometry and RT-qPCR data from the paper support this (actin H73 methylation undetectable in SETD3-5M complemented cells while replication restored) SETD3-5M rescue data

Mechanistic strengths (what the paper shows well)

• Complementary, orthogonal approaches: genome-wide CRISPR screens (GeCKO), isogenic SETD3KO lines, rescue with WT and mutant SETD3, replicon/electroporation assays that separate entry/translation from replication, AP‑MS and co-IP, mammalian two-hybrid alanine scan, and neonatal mouse infection models — consistent results across assays strengthen causal inference Multi-modal evidence
• High specificity: SETD3 dependency is broad across human Enterovirus species (rhinoviruses, EV‑D68, CV-A10, PV-1) yet absent for EMCV (cardiovirus), highlighting a genus-specific host dependency and minimizing a generic cell‑health artefact explanation Species-specific dependency

Mechanistic uncertainties, blindspots and limitations

• Non-catalytic mechanism is shown, but the biochemical activity by which SETD3 promotes replication remains undefined: the paper demonstrates binding to viral 2A and necessity for replication, but how SETD3 structurally or biochemically enables RNA amplification (scaffolding replication complexes, remodeling membranes, recruiting host factors, or affecting viral protein conformation) is unresolved 2A–SETD3 interaction without mechanistic detail
• Overexpression/complementation risks: many rescue experiments use lentiviral expression (CMV or TRE promoters). Although authors used minimal promoters for some constructs and verified localization dependence (NES vs NLS), overexpression can create non-physiological PPIs — further experiments with endogenous-level knockin complementation would remove residual doubt Complementation approaches and caveats
• Mouse model context: neonatal intracerebral or intramuscular inoculation in 2-day-old pups is a stringent test of pathogenesis but may not model adult human respiratory or neurological infection dynamics; however, the complete protection of Setd3−/− neonates is a strong phenotype and supports physiological importance for pathogenesis In vivo neonatal protection
• Generality across tissues/species and long-term effects: SETD3 has roles in actin methylation and development in some models; Setd3−/− mice are viable but potential subtle phenotypes or tissue-specific vulnerabilities (e.g., in adults) should be mapped before host-targeting therapies are proposed Setd3 knockout viability and unknowns

Interpretation and implications

Key takeaways: (1) SETD3 is a bona fide, broadly required host factor for human enteroviruses; (2) Enteroviral 2A protease binds SETD3 on a surface distinct from its catalytic site, and this binding (not protease activity nor SETD3 catalytic methylation) is necessary for RNA replication; (3) Targeting the SETD3–2A interaction, rather than SETD3 catalytic site, is the most logical antiviral strategy from these data.

This suggests host-directed antivirals that disrupt the SETD3–2A interface (small molecules, stapled peptides, or targeted degraders) might provide broad-spectrum anti-enterovirus activity while avoiding direct selection for viral resistance. However, safety (long-term SETD3 inhibition effects) and adult/tissue-specific roles remain to be established before translation.

Concrete next experiments (high value, falsifiable)

1. Endogenous knockin complementation: create SETD3 alleles with point mutations that ablate 2A binding but preserve other interactions (CRISPR knockin) in human cell lines; test viral replication to show loss-of-function at physiological expression levels (falsifies overexpression artefact concerns).
2. Biochemistry of replication organelles: use proximity proteomics (APEX/TurboID) on 2A and SETD3 during infection and map co-recruited host factors (PI4KB, ACBD3, OSBP, etc.) to test whether SETD3 organizes replication membranes or recruits lipid/host factors required for RNA amplification.
3. Structural biology: solve a co-crystal or cryo-EM structure of the SETD3 RSB/SET domain (or minimal binding fragment) bound to 2A (or 2A surface peptide) to enable rational inhibitor design blocking the interface.
4. Adult and tissue-specific phenotyping: longitudinally examine Setd3−/− adult mice for immune, neuromuscular, and respiratory phenotypes and test adult infection models to evaluate translational safety margins.

Confidence & short critical appraisal

Overall, the evidence is coherent and convergent across independent approaches and model systems. The strongest claims (SETD3 is required for enteroviral RNA replication and that 2A–SETD3 binding is functionally necessary) are well supported. The principal open question is biochemical mechanism of action (non-catalytic) — a deep, tractable mechanistic problem that the field can address with structural and proximity-proteomics experiments.

Sources used (primary):

All claims and figures above are directly drawn from and summarized with the primary article: Diep et al., Nature Microbiology (2019) Diep et al., Nature Microbiology 2019